Drug Trial Radar · NCT04008706
Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients
Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
552
Actual
Start
Sep 17, 2019
Primary completion
Nov 4, 2025
Study completion Nov 4, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Jul 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a global, Phase IIIb, multicenter, open-label, single-arm study to evaluate the safety and efficacy of acalabrutinib 100 mg twice daily (bid) in approximately 540 participants with chronic lymphocytic leukemia (CLL). Participants will be enrolled into 3 following cohorts: treatment-naive (TN), relapsed/refractory (R/R), and prior ibrutinib therapy. For this study, participants in the UK will be enrolled ONLY into the R/R cohort or the prior ibrutinib cohort. Participants in the US will be enrolled ONLY into the TN or R/R cohort. Participants will remain on study intervention until completion of 48 cycles (28 days per cycle), or until study intervention discontinuation due to, for example disease progression, or toxicity, withdrawal of consent, loss to follow-up, death, or study termination by the sponsor whichever occurs first. The duration of the study will be approximately 72 months from the first participant enrolled. This duration includes an estimated 24-month recruitment time and an assumed 48 cycles of study intervention (28 days per cycle); additional study time will be accrued during the Disease Follow up period for those participants remaining on study intervention after completion of 48 cycles prior to the final data cutoff (DCO) (the amount of time will vary by participant).
Conditions
- Chronic Lymphocytic Leukemia
Interventions
AcalabrutinibDrug
Acalabrutinib will be administered as one 100 mg capsule taken orally, twice daily with 8 ounces (approximately 240 mL) of water.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs)Time frame: Up to safety follow-up period (about 30 days from last dose) (approximately 74 months)
Locations
108 sites in 17 countries. Site status is shown where the registry gives one.
Research Site
Chandler, Arizona
Research Site
Long Beach, California
Research Site
Redlands, California
Research Site
Whittier, California
Research Site
Fort Myers, Florida
Research Site
Jacksonville, Florida
Research Site
St. Petersburg, Florida
Research Site
Marietta, Georgia
Research Site
Normal, Illinois
Research Site
Peoria, Illinois
Research Site
Fort Wayne, Indiana
Research Site
Indianapolis, Indiana
Research Site
Shreveport, Louisiana
Research Site
Saint Cloud, Minnesota
Research Site
Kansas City, Missouri
Research Site
Bethlehem, Pennsylvania
Research Site
Chattanooga, Tennessee
Research Site
Nashville, Tennessee
Research Site
Dallas, Texas
Research Site
Adelaide, Australia
Research Site
Bedford Park, Australia
Research Site
Clayton, Australia
Research Site
Fitzroy, Australia
Research Site
Nedlands, Australia
Research Site
South Brisbane, Australia
Research Site
Belo Horizonte, Brazil
Research Site
Curitiba, Brazil
Research Site
Goiânia, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Ribeirão Preto, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Calgary, Alberta, Canada
Research Site
Edmonton, Alberta, Canada
Research Site
Victoria, British Columbia, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
Halifax, Nova Scotia, Canada
Research Site
Brampton, Ontario, Canada
Research Site
Newmarket, Ontario, Canada
Showing 40 of 108 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.